Navigation Links
Romark Announces Clinical Trial Results for New Influenza Drug Presented at IDSA Meeting 2011
Date:10/21/2011

Jason Haffizulla, Harvey Resnick, Aaron Hartman, Stefan Comhaire, Maria Carríon, Matthew Bardin. Presentation Number LB-35, Session 182a: Late Breaker Oral Abstracts - Clinical Virology and Treatment. Saturday, October 22, 2011, 6:30 PM.

About the US Clinical Trial

The clinical trial was conducted in 74 outpatient primary care centers throughout the United States during the 2010-2011 flu season.  624 patients, 12 to 65 years of age, with influenza symptoms were enrolled in the study within 48 hours of symptom onset and received treatment with 300 mg NTZ, 600 mg NTZ or placebo twice daily for 5 days.  Patients who received an influenza vaccine after August 1, 2010 and patients at risk of complications of influenza based upon CDC or IDSA criteria were excluded from participation in the trial. The study was designed according to FDA Guidance and consistent with prior clinical trials of Tamiflu® and Relenza®. The primary efficacy endpoint of the study was time from first dose to alleviation of symptoms (all symptoms absent or mild and remain so for 24 hours).  

Two hundred and fifty-seven (257) of the 624 patients enrolled in the study (41%) had laboratory confirmed influenza infection by RT-PCR or viral culture at baseline. Approximately half of the influenza-infected patients enrolled in the US clinical trial were infected with influenza A subtype H1N1 ("swine flu") with approximately 30% being infected with influenza B and 20% with influenza A subtype H3N2. The trial achieved its primary endpoint showing that influenza-infected patients treated with NT-300 administered 600 mg twice daily for five days experienced statistically significant reduction in time from beginning treatment to alleviation of flu symptoms compared to influenza-infected patients receiving the placebo (P=0.008). Median time to alleviation of symptoms was 95.5 hours for the 600 mg dose group compared to 109.1 hours for the 300 mg do
'/>"/>

SOURCE Romark Laboratories, L.C.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Romark Laboratories Raises $18 Million in Institutional Financing
3. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
4. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008
5. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
6. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
7. NeuroFocus and New Scientist Magazine Apply Neuromarketing to Select Cover Design
8. Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
9. Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C
10. Romark Announces Data Presented at AASLD Meeting 2010
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015  Following a bipartisan vote ... moved H.R. 284, the Medicare DMEPOS Competitive Bidding ... for Homecare (AAHomecare) released a statement praising the ... pass the legislation. "Today,s mark-up of ... Ways and Means Committee is a critical step ...
(Date:2/27/2015)... HOUSTON, TX , Feb. 27, 2015 /PRNewswire/ ... and Bloom Burton & Co. Ltd. ("Bloom Burton") today ... (the "Lock-Up") 2,353,130 common shares of the Company ("Common ... to the Lock-Up. Of the Common Shares released from ... upon release from the Lock-Up while the remainder will ...
(Date:2/27/2015)... 2015   Synageva BioPharma Corp. (Synageva) ... developing therapeutic products for rare diseases, joins the ... Organisation for Rare Diseases™ (EURORDIS™), The Global Genes ... Rare Disease Day. On the last ... and other participants conduct special events to raise ...
Breaking Medicine Technology:Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6
... Inc. (Nasdaq:GILD) today announced that Study 103, ... once-daily,anti-HIV drug Viread(R) (tenofovir disoproxil fumarate or ... for chronic hepatitis B virus,(HBV) infection, met ... Viread is non-inferior to the company's once-daily ...
... study demonstrates 75% of patients receiving highest ... June 25, 2007 /PRNewswire-FirstCall/ -- According to,findings ... of the,American Diabetes Association (ADA) in Chicago, ... dose of human,GLP-1 analog under development by ...
Cached Medicine Technology:Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 2Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 3Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 6Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target 2Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target 3Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target 4
(Date:2/28/2015)... My Shiney Hiney® LLC., the renowned brand ... Las Vegas, Nevada for the annual ASD Market Week tradeshow. ... leading consumer-goods tradeshows and My Shiney Hiney will be one ... Shiney Hiney can be found at booth number C1663. , ... at-home personal hygiene brush and cleansing system exclusively created to ...
(Date:2/27/2015)... 27, 2015 OnChip Devices , ... introduced miniature, wire bondable, silicon ESD (Electrostatic Discharge) protection ... The ESD88NP and ESD88PN ... sensitive LED and IC products. These Zeners exhibit ... All devices meet the requirements of IEC61000 and ...
(Date:2/27/2015)... 2015 Today, February 27th, is "Shine A ... along with LXR Organics and Living Fuel, ... to raise awareness and promote prevention, rescue and restoration for ... the END IT Coalition, slavery is the 2nd largest global ... in 167 countries around the world. Slavery includes bonded labor, ...
(Date:2/27/2015)... Altec Products, Inc., announced today that ADSS ... Management Partner of the Year. ADSS Global provides Sage ... complimentary solutions for their customers across the world. Altec ... to provide clients with paperless solutions that integrate seamlessly ... thrilled to recognize ADSS Global for their expertise in ...
(Date:2/27/2015)... Calif. (PRWEB) February 27, 2015 ... who are documented to use Medicaid, the federal ... families, according to a new study from UC ... the greatest predictor of farmworker use of Medicaid, ... care regardless of documentation status, was having children. ...
Breaking Medicine News(10 mins):Health News:My Shiney Hiney® to Participate in ASD Market Week 2015 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 3Health News:KAJ Brothers Join the Campaign to 'End It - Shine A Light On Slavery' 2Health News:Altec Announces 2014 Sage ERP Document Management Partner of the Year Award Recipient 2Health News:UC Davis Study Finds Undocumented Farmworkers Use Medicaid Half as Often as Documented Farmworkers 2Health News:UC Davis Study Finds Undocumented Farmworkers Use Medicaid Half as Often as Documented Farmworkers 3
... Discusses key issues ... ... only on motivating employees, but also on how supportive companies are of the program, according ... High-Engagement Wellness Program , scheduled for Thursday, April 22 at 3:00 pm EST, Fiona Gathright, ...
... Medication offers hope for treatment with fewer side effects, experts ... reporting that a drug is showing promise in early testing ... and potentially deadly liver ailment. , It,s too early to ... years before it,s ready to seek federal approval to be ...
... discovery 15 years ago that the genes BRCA1 and ... was a breakthrough for cancer prediction and therapy, especially ... Alfons Meindl (Klinikum rechts der Isar of the Technische ... the U.K., and the U.S., can identify another gene ...
... Dr. ... of skin care products that claim to be "natural" or "organic" have cancer-causing ingredients. ... New York, NY (PRWEB) April ... recent study: a number of skin care products that claim to be "natural" or "organic" ...
... ... that allows unlimited penetration testing against your environment to help achieve compliance, such as ... , ... 21, 2010 -- Clone Systems, Inc. has introduced Clone Guard® CG-PenTest, a web portal ...
... D.C. (April 21, 2010)Past randomized clinical trials have ... can reduce the risk of colon cancer and ... Chase Cancer Center have found that an investigational ... can block one of the earliest molecular changes ...
Cached Medicine News:Health News:DSM Personalized Nutrition Webinar Examines Ways to Build Engagement in Wellness Programs 2Health News:DSM Personalized Nutrition Webinar Examines Ways to Build Engagement in Wellness Programs 3Health News:In Early Test, New Hepatitis C Drug Shows Promise 2Health News:Researchers identify a new breast and ovarian cancer susceptibility gene 2Health News:Carcinogen Found in Many "Natural" Skin Care Products, One Skin Care Specialist Fights Back 2Health News:Clone Systems, Inc. Introduces On-Demand Penetration Testing Service 2Health News:Researchers show that nitric oxide-donating naproxen can boost colorectal cancer prevention 2
... CDI creates a smoother fit in the ... patient. The padded continuous hook and eye ... and the extra strong, yet very thin ... as a reinforced open crotch, gripper lace ...
This compression garment can be used immediatlely following Abdominoplasty, Tram Flap, Abdominal Liposuction, Lipoplasty, Suction Lipectomy, Stomach Liposuction, Liposculpture and Tummy Tuck procedur...
This compression garment can be used immediatlely following Abdominoplasty, Tram Flap, Abdominal Liposuction, Lipoplasty, Suction Lipectomy, Stomach Liposuction, Liposculpture and Tummy Tuck procedur...
Short Girdle, Mid-thigh, Front Closure...
Medicine Products: